We are live on ! Find out more

Vertex Pharmaceuticals

VRTX

Market cap $133B

524.15 USD

-4.75

0.9%

At close Updated Sep 9, 9:44 AM EDT

1 day

-0.9%

5 days

-5.12%

1 month

0.05%

3 months

17.58%

6 months

13.73%

Year to date

15.93%

1 year

32.2%

5 years

178.67%

10 years

459.51%

About: Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Employees: 6,400

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 53.1%

Neutral 40.6%

Negative 6.3%

Zacks Investment Research

Vertex Pharmaceuticals (VRTX) Suffers a Larger Drop Than the General Market: Key Insights

In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $528.9, indicating a -3.15% shift from the previous trading day.

Vertex Pharmaceuticals (VRTX) Suffers a Larger Drop Than the General Market: Key Insights

The Motley Fool

Goldman Sachs Just Added Vertex Pharmaceuticals to Its Conviction List. Here's the Bull Case for the Big Biotech Stock

Vertex Pharmaceuticals' core business is rock-solid, but it is also slowly expanding into new areas. The company should see improved top-line growth over the next few years, driven by new launches.

Goldman Sachs Just Added Vertex Pharmaceuticals to Its Conviction List. Here's the Bull Case for the Big Biotech Stock

Zacks Investment Research

Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know

Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know

Rep. David Taylor discloses 6 new Congressional stock trades

Representative David J. Taylor, a Republican from Ohio, has reported six congressional stock trades, selling off holdings in biotech and technology while purchasing shares in utility, semiconductor, and a regional bank.

Rep. David Taylor discloses 6 new Congressional stock trades

The Motley Fool

Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now?

Vertex Pharmaceuticals is slowly but surely expanding beyond its highly successful core therapeutic area. Regeneron has successfully rebounded after facing biosimilar competition for a key growth driver, and it boasts several attractive pipeline candidates.

Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now?

The Motley Fool

3 Stocks Whose Competitive Walls Tower Over Nvidia's

Tech giant Nvidia has remained ahead of rivals thanks to its competitive advantage. These healthcare companies have proven expertise in their fields -- and they would be difficult to unseat.

3 Stocks Whose Competitive Walls Tower Over Nvidia's

Zacks Investment Research

Why Is Vertex (VRTX) Up 14.4% Since Last Earnings Report?

Vertex (VRTX) reported earnings 30 days ago. What's next for the stock?

Why Is Vertex (VRTX) Up 14.4% Since Last Earnings Report?

Vertex Completes Acquisition of Crinetics Pharmaceuticals and Announces Expansion of Executive Leadership Team

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the successful completion of the acquisition of Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases. Vertex also announced the expansion of its executive leadership team, in support of the Company's continued growth and diversification. Completion of Acquisition of Crinetic.

Vertex Completes Acquisition of Crinetics Pharmaceuticals and Announces Expansion of Executive Leadership Team

Vertex to Participate in Upcoming September Investor Conferences

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in four upcoming investor conferences. Susie Lisa, Senior Vice President of Investor Relations and Manisha Pai, Executive Director of Investor Relations, will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026, at 4:30 p.m. EDT. Susie Lisa and Manisha Pai will also participate in a fireside chat at the 2026 Cantor G.

Vertex to Participate in Upcoming September Investor Conferences

Zacks Investment Research

Vertex Pharmaceuticals Up 15% in a Month: How to Play the Stock

Vertex's stock is up 15% in a month as strong CF sales, rising non-CF drug revenues and renal pipeline progress boost its growth story.

Vertex Pharmaceuticals Up 15% in a Month: How to Play the Stock

See News Rankings

Price charts implemented using Lightweight Charts™